Document is current
Any future updates will be listed below
-
Authors
Yki-Järvinen, Hannele https://orcid.org/0000-0001-6766-1549
Roden, Michael https://orcid.org/0000-0001-8200-6382
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 9 March 2026
Accepted: 31 March 2026
First Online: 15 August 2026
Ethics
Acknowledgements: The authors wish to thank A. Krämer at the German Diabetes Center (DDZ) for helping with the organisation of the references.
Funding: Open Access funding enabled and organized by Projekt DEAL. MR’s research is supported in part by the German Diabetes Center (DDZ), which is funded by the German Federal Ministry of Health (Berlin, Germany) and the Ministry of Culture and Science of the state of North Rhine-Westphalia (Düsseldorf, Germany), by grants from the German Federal Ministry of Research, Technology and Space (Berlin, Germany) to the German Center for Diabetes Research e.V. (DZD e.V.), and by grants from the Schmutzler Stiftung, the German Research Foundation (DFG) (CRC 1774) and the European Community (HORIZON-HLTH-2022-STAYHLTH-02–01: Panel A) to the INTERCEPT-T2D consortium.
Authors’ relationships and activities: HY-J has received fees for consulting from Novartis, Novo Nordisk, Eli Lilly, Hanmi Pharmaceuticals and MSD. MR has received fees for consulting or lecturing from Astra Zeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk, Sanofi, Synlab and Target RWE and has performed investigator-initiated research with support from Boehringer Ingelheim and Novo Nordisk.
Contribution statement: Both authors were responsible for drafting the article and reviewing it critically for important intellectual content. Both authors approved the version to be published.
